MCID: THR001
MIFTS: 55

Thrombocytopenia Due to Platelet Alloimmunization

Categories: Rare diseases, Blood diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 15 73
Immune Thrombocytopenia 12 76 53 25 37 63
Autoimmune Thrombocytopenia 25 29 55 73
Immune Thrombocytopenic Purpura 25 73
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 25
Autoimmune Thrombocytopenic Purpura 25
Auto-Immune Thrombocytopenia 12
Werlhof Disease 25
Itp 25

Classifications:



External Ids:

Disease Ontology 12 DOID:1587
NCIt 50 C3991
SNOMED-CT 68 2897005
KEGG 37 H01240

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

PubMed Health : 63 About immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites).Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as immune thrombocytopenia, is related to thrombocytopenic purpura, autoimmune and thrombocytopenia. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is IFNG-AS1 (IFNG Antisense RNA 1
TMEVPG1 could promote IFNG transcription, and IFNG over-expression negative feedback regulated on TMEVPG1 expression, which resulted in decreased TMEVPG1 in ITP patients.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Phagosome and Osteoclast differentiation. The drugs Dexamethasone and Amodiaquine have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and prostate, and related phenotypes are hematopoietic system and homeostasis/metabolism

Genetics Home Reference : 25 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cell fragments called platelets that are needed for normal blood clotting.

Wikipedia : 76 Immune thrombocytopenia (ITP) is a type of thrombocytopenic purpura defined as isolated low platelet... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Myh9 Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenic purpura, autoimmune 30.5 FCGR2C ITGA2B MPL SELP THPO
2 thrombocytopenia 27.7 ITGA2 ITGA2B MPL MYH9 THPO
3 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.0
4 evans' syndrome 11.1
5 thrombocytopenia 3 10.4 MPL THPO
6 thrombocythemia 1 10.4 MPL THPO
7 amegakaryocytic thrombocytopenia, congenital 10.4 MPL THPO
8 dyskeratosis congenita, autosomal dominant 6 10.3 MPL THPO
9 autosomal dominant macrothrombocytopenia 10.3 ITGA2B MYH9
10 carotid artery thrombosis 10.3 ITGA2B SELP
11 thrombocytopenia 1 10.2 SELP THPO
12 fetal and neonatal alloimmune thrombocytopenia 10.2 ITGA2 ITGA2B
13 leukocyte adhesion deficiency, type iii 10.2 ITGA2B SELP
14 intermediate coronary syndrome 10.2 ITGA2B SELP
15 thrombocytopenia-absent radius syndrome 10.0 MPL THPO
16 splenic disease 9.9 CD40LG THPO
17 early congenital syphilis 9.8 CD40LG MYH9
18 primary syphilis 9.8 CD40LG MYH9
19 aplastic anemia 9.8 ITGA2B MPL THPO
20 tertiary syphilis 9.8 CD40LG MYH9
21 latent syphilis 9.8 CD40LG MYH9
22 pancytopenia 9.8 MPL THPO
23 heparin-induced thrombocytopenia 9.8 CD40LG SELP
24 thrombocytosis 9.8 MPL SELP THPO
25 granulomatous hepatitis 9.8 CD40LG ITGA2B
26 congenital syphilis 9.8 CD40LG MYH9
27 polycythemia vera 9.8 MPL SELP THPO
28 asymptomatic neurosyphilis 9.8 CD40LG MYH9
29 bone marrow cancer 9.7 MPL SELP THPO
30 ehrlichiosis 9.7 CD40LG SELP
31 idiopathic neutropenia 9.7 CD40LG THPO
32 legg-calve-perthes disease 9.7 CD40LG SELP
33 dengue disease 9.7 CD40LG THPO
34 megakaryocytic leukemia 9.7 ITGA2B THPO
35 thrombasthenia 9.6 ITGA2 ITGA2B SELP
36 glanzmann thrombasthenia 9.6 ITGA2 ITGA2B SELP
37 syphilis 9.6 CD40LG MYH9
38 tertiary neurosyphilis 9.6 CD40LG MYH9
39 exanthema subitum 9.5 CD40LG ITGA2B THPO
40 immune system disease 9.5 CD40LG ITGA2B THPO
41 gray platelet syndrome 9.5 CD40LG SELP
42 essential thrombocythemia 9.4 ITGA2B MPL SELP THPO
43 antiphospholipid syndrome 9.3 CD40LG SELP
44 hematologic cancer 9.3 CD40LG MPL THPO
45 bernard-soulier syndrome 9.2 ITGA2 ITGA2B MYH9 THPO
46 purpura 9.0 CD40LG ITGA2B MPL THPO
47 myocardial infarction 8.6 CD40LG ITGA2 ITGA2B SELP
48 blood coagulation disease 8.4 CD40LG ITGA2B MPL SELP THPO
49 hemorrhagic disease 8.4 CD40LG ITGA2B MPL MYH9 THPO
50 autoimmune disease of blood 8.3 CD40LG ITGA2 ITGA2B MPL THPO

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 CD40LG ITGA2 ITGA2B MPL MYH9 SELP
2 homeostasis/metabolism MP:0005376 9.17 CD40LG ITGA2 ITGA2B MPL MYH9 SELP

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

PubMedHealth treatment related to Thrombocytopenia Due to Platelet Alloimmunization: 63

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count.Adults who have mild ITP may not need any treatment, other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated.The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura), usually are treated.Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 929)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
2
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
3
Artemether Approved Phase 4,Phase 3 71963-77-4 119380 68911
4
Artesunate Approved, Investigational Phase 4,Not Applicable 88495-63-0 6917864 5464098
5
Dihydroartemisinin Approved, Investigational Phase 4,Phase 3,Phase 2 71939-50-9 6918483
6
Lumefantrine Approved Phase 4,Phase 3 82186-77-4 6437380
7
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
8
Piperaquine Approved, Investigational Phase 4,Phase 3,Phase 2 4085-31-8 5079497
9
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
12
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2 50-28-2 5757
13 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2 979-32-8
14
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
15
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
16
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
17
Polyestradiol phosphate Approved Phase 4,Phase 2 28014-46-2
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
19
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2447-57-6 17134
20
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
21
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
22
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
23
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
24
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
25
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
26
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
27
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
28
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
29
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
30
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
32
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 5284616 6436030 46835353
33
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
34
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
35
Hydroxychloroquine Approved Phase 4 118-42-3 3652
36
Dinoprostone Approved Phase 4 363-24-6 5280360
37
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
38
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
39
Ezetimibe Approved Phase 4 163222-33-1 150311
40
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 79902-63-9 54454
41
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
42
Lopinavir Approved Phase 4 192725-17-0 92727
43
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
44
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
45
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
46
Rosiglitazone Approved, Investigational Phase 4,Phase 1,Not Applicable 122320-73-4 77999
47
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
48
Acetylcysteine Approved, Investigational Phase 4,Phase 3 616-91-1 12035
49
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
50
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969

Interventional clinical trials:

(show top 50) (show all 1515)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
3 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
4 Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols Unknown status NCT00742807 Phase 4 Low dose of alfentanil hydrochloride;Normal dose of alfentanil hydrochloride
5 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
6 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Unknown status NCT01296191 Phase 4 Moxifloxacin;besifloxacin
7 Graz Study on the Risk of Atrial Fibrillation Unknown status NCT01461434 Phase 4
8 A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques Unknown status NCT02532309 Phase 4 Rosuvastatin (5mg,10mg,20mg);Rosuvastatin 5mg
9 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
10 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
11 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
12 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
13 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
14 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
15 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
16 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
17 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
18 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT01390649 Phase 4
19 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
20 A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification Completed NCT01021761 Phase 4 Ketorolac Tromethamine;Bromfenac;nepafenac
21 A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification Completed NCT01001806 Phase 4 Ketorolac Tromethamine 0.45%;bromfenac 0.09%;nepafenac 0.1%
22 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed NCT00817843 Phase 4 Simvastatin;Simvastatin/Ezetimibe
23 Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis Completed NCT00822640 Phase 4
24 Treatment of Depression in Adults Completed NCT00073697 Phase 4 Escitalopram
25 Raltegravir Kaletra Pharmacokinetics Completed NCT00564772 Phase 4 Raltegravir, lopinavir, ritonavir
26 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects Completed NCT00469690 Phase 4 Acular, Xibrom
27 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
28 A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID) Completed NCT01023724 Phase 4 Ketorolac Tromethamine 0.45%;Bromfenac 0.09%
29 Effect of Thiazolidinedione Treatment Vascular Risk Markers Completed NCT00571506 Phase 4 Rosiglitazone;Pioglitazone
30 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
31 Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion Completed NCT00188773 Phase 4 N-acetylcysteine, intralipid, heparin
32 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
33 Mechanism of Growth Hormone Effects on Adipose Tissue Completed NCT00453557 Phase 4 rhGH
34 "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM Completed NCT00402012 Phase 4 Pioglitazone
35 Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients Completed NCT00347503 Phase 4 ketorolac 0.4%, bromfenac 0.09%
36 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
37 Oat Breakfast Satiety Study Completed NCT01372683 Phase 4
38 Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine Completed NCT00975325 Phase 4 Yohimbine;Yohimbine
39 Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
40 Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder Completed NCT00227968 Phase 4
41 Comparing Various Treatments for Achieving and Maintaining Remission of Depression Completed NCT00227955 Phase 4 Imipramine
42 Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
43 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
44 Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent? Completed NCT01091714 Phase 4
45 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA) Completed NCT00094575 Phase 4
46 Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function Completed NCT00189085 Phase 4 simvastatin and ezetimibe
47 Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study Completed NCT00222820 Phase 4 escitalopram
48 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4 Desipramine
49 Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial Completed NCT00751361 Phase 4
50 Cryoplasty CLIMB-registry Completed NCT00459888 Phase 4

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 29 FCGR2C

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

41
Lung, Heart, Prostate, Bone, Testes, Kidney, Liver

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 483)
# Title Authors Year
1
Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis. ( 29402802 )
2018
2
Reduced PTEN involved in primary immune thrombocytopenia via contributing to B cell hyper-responsiveness. ( 29175594 )
2018
3
Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-I_B/SMAD pathway in patients with immune thrombocytopenia. ( 29327472 )
2018
4
IL-10 polymorphisms and T-cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population. ( 29696721 )
2018
5
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. ( 29357781 )
2018
6
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. ( 29380254 )
2018
7
Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. ( 29442265 )
2018
8
Subacute sclerosing panencephalitis and immune thrombocytopenia: More than a coincidence? ( 29407001 )
2018
9
Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia. ( 29313460 )
2018
10
Diminished expression of I^2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. ( 29350259 )
2018
11
Immune dysregulation in primary immune thrombocytopenia patients. ( 29409398 )
2018
12
Immune Thrombocytopenia in a Child With Refractory Langerhans Cell Histiocytosis Following Cladribine Containing Therapy. ( 29889804 )
2018
13
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. ( 29978577 )
2018
14
Intravenous immunoglobulin versus observation in childhood immune thrombocytopenia: a randomized controlled trial. ( 29945954 )
2018
15
Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. ( 29330464 )
2018
16
A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. ( 29516627 )
2018
17
Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report. ( 29981476 )
2018
18
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. ( 29978544 )
2018
19
Adult Primary Immune Thrombocytopenia: Spleen Histology Findings and Outcomes According to Rituximab Use Based on Analysis of 41 Cases. ( 29200102 )
2018
20
State of the art - how I manage immune thrombocytopenia. ( 28295192 )
2017
21
FcI^ receptor expression on splenic macrophages in adult immune thrombocytopenia. ( 28142207 )
2017
22
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. ( 28073042 )
2017
23
Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia. ( 28952160 )
2017
24
Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. ( 28917657 )
2017
25
[Comparative study between two bleeding grading systems of primary immune thrombocytopenia]. ( 28565738 )
2017
26
Decreased TLR4 expression on monocytes may cause regulatory T cells abnormality in patients with primary immune thrombocytopenia. ( 28412855 )
2017
27
[Predictors of fatigue among individuals with primary immune thrombocytopenia in China]. ( 28565736 )
2017
28
Delayed Appearance of Cutaneous Lesions of Cutaneovisceral Angiomatosis (CAT) Leading to Misdiagnosis of Immune Thrombocytopenia. ( 28234740 )
2017
29
Acquired Generalized Lipodystrophy Following Immune Thrombocytopenia. ( 28549922 )
2017
30
Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. ( 28142109 )
2017
31
FC gamma receptor polymorphisms in patients with immune thrombocytopenia. ( 28942727 )
2017
32
Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. ( 28078756 )
2017
33
Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. ( 28240787 )
2017
34
Is oral all-trans retinoic acid plus danazol a refinement of second-line therapy for primary immune thrombocytopenia in adults? ( 28917656 )
2017
35
Association Between TNF-I+ -308G/A Polymorphism and Risk of Immune Thrombocytopenia: A Meta-Analysis. ( 27960071 )
2017
36
Management of newly diagnosed immune thrombocytopenia: can we change outcomes? ( 29296878 )
2017
37
Immune Thrombocytopenia and Obesity: Predictive Relationship. ( 28331458 )
2017
38
A gain-of-function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia. ( 28834165 )
2017
39
Increase of C3a is Associated with Hemorrhagic Propensity in Patients with Immune Thrombocytopenia. ( 28397467 )
2017
40
Persistent immune thrombocytopenia heralds the diagnosis of <i>Mycobacterium chimaera</i> prosthetic valve endocarditis. ( 27909685 )
2017
41
Decreased Frequency of IL-17F rs763780 Site Allele G is Associated With Genetic Susceptibility to Immune Thrombocytopenia in a Chinese Population. ( 26620416 )
2017
42
Babesiosis-associated immune thrombocytopenia. ( 28217703 )
2017
43
Re: Severe Primary Autoimmune Thrombocytopenia (ITP) in Pregnancy: a national cohort study Primary immune thrombocytopenia management during pregnancy. A French study. ( 28940981 )
2017
44
Impaired function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia patients in inducing regulatory DC differentiation via the Notch-1/Jagged-1 signaling pathway. ( 28946811 )
2017
45
Immune Thrombocytopenia as a Consequence of Rocky Mountain Spotted Fever. ( 29279696 )
2017
46
B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. ( 27863820 )
2017
47
Immune thrombocytopenia of childhood responsive to tonsillectomy in the setting of chronic tonsillitis: A case report and literature review. ( 28648251 )
2017
48
Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide. ( 28052942 )
2017
49
Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient. ( 28950270 )
2017
50
From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. ( 28473904 )
2017

Variations for Thrombocytopenia Due to Platelet Alloimmunization

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to KEGG:

37
# Name Kegg Source Accession
1 Phagosome hsa04145
2 Osteoclast differentiation hsa04380
3 Fc gamma R-mediated phagocytosis hsa04666

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.56 CD40LG ITGA2 ITGA2B MPL
2 external side of plasma membrane GO:0009897 9.26 CD40LG ITGA2 ITGA2B SELP
3 platelet alpha granule membrane GO:0031092 9.16 ITGA2B SELP
4 integrin complex GO:0008305 8.8 ITGA2 ITGA2B MYH9

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.67 ITGA2 ITGA2B MYH9 SELP
2 integrin-mediated signaling pathway GO:0007229 9.43 ITGA2 ITGA2B MYH9
3 leukocyte cell-cell adhesion GO:0007159 9.32 CD40LG SELP
4 thrombopoietin-mediated signaling pathway GO:0038163 9.16 MPL THPO
5 platelet aggregation GO:0070527 9.13 ITGA2B MPL MYH9
6 positive regulation of leukocyte migration GO:0002687 8.8 ITGA2 ITGA2B SELP

Sources for Thrombocytopenia Due to Platelet Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....